PensionDanmark Pensionsforsikringsaktieselskab Raises Position in Abbott Laboratories $ABT

Key Points

• PensionDanmark increased its Abbott Laboratories stake by 16.2% in the second quarter, adding 47,845 shares to hold 342,554 shares valued at approximately $31.1 million. Institutional investors collectively own 75.18% of Abbott’s stock.
• Analysts remain broadly positive, with a consensus “Moderate Buy” rating and an average price target of $118.17, although several firms recently lowered their targets.
• Abbott exceeded quarterly expectations with $1.31 in EPS and $12.59 billion in revenue, up 13% year over year. The company also declared a quarterly dividend of $0.63 per share, equivalent to a 2.3% annual yield.

PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 16.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 342,554 shares of the healthcare product maker's stock after buying an additional 47,845 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab's holdings in Abbott Laboratories were worth $31,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter worth approximately $25,000. MidAtlantic Capital Management Inc. acquired a new position in Abbott Laboratories during the 4th quarter valued at approximately $25,000. Purpose Unlimited Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth $26,000. Finally, Abound Financial LLC acquired a new stake in shares of Abbott Laboratories during the fourth quarter worth $26,000. Institutional investors and hedge funds own 75.18% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently issued reports on ABT shares. Evercore cut their target price on Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. UBS Group dropped their price target on Abbott Laboratories from $135.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday, July 28th. Citigroup increased their price objective on Abbott Laboratories from $108.00 to $112.00 and gave the company a "buy" rating in a report on Friday, July 17th. Barclays reduced their price objective on Abbott Laboratories from $144.00 to $143.00 and set an "overweight" rating for the company in a research note on Monday, April 20th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $118.00 target price (up from $115.00) on shares of Abbott Laboratories in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $118.17.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $107.86 on Friday. Abbott Laboratories has a 52-week low of $81.97 and a 52-week high of $137.49. The company has a quick ratio of 0.97, a current ratio of 1.38 and a debt-to-equity ratio of 0.57. The stock has a market cap of $186.63 billion, a PE ratio of 34.90, a price-to-earnings-growth ratio of 2.05 and a beta of 0.59. The business has a 50-day simple moving average of $95.06 and a 200-day simple moving average of $99.97.

Abbott Laboratories (NYSE:ABT - Get Free Report) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analyst estimates of $12.52 billion. Abbott Laboratories had a return on equity of 17.69% and a net margin of 11.65%.Abbott Laboratories's revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the company earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, equities analysts expect that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Stockholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's payout ratio is 81.55%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source